1. Viral contamination in biologic manufacture and implications for emerging therapies
2. Outbreak of hepatitis C associated with intravenous immunoglobulin administration—United States, October 1993–June 1994;Centers for Disease Control and Prevention;MMWR Morb Mortal Wkly Rep,1994
3. Emerging viral infections—a potential threat for blood supply in the 21st century;Mendoza C;AIDS Rev,2012
4. ICH.Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin.Q5A Guideline.1999.
5. EMA.Note for guidance on plasma‐derived medicinal products. CPMP/BWP/269/95.2001.